We are live on ! Find out more
SWTX icon

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

141 hedge funds and large institutions have $2.86B invested in SpringWorks Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 59 increasing their positions, 37 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 37

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

30% more call options, than puts

Call options by funds: $317K | Put options by funds: $243K

18% more capital inflows, than outflows

Capital inflows: $292M | Capital outflows: $248M

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

5% more funds holding

Funds holding: 134 → 141 (+7)

0.38% more ownership

Funds ownership: 91.19% → 91.58% (+0.38%)

Holders
141
Holders Change
+7
Holders Change %
+5.22%
% of All Funds
2.46%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
16
Increased
59
Reduced
37
Closed
11
Calls
$317​K
Puts
$243​K
Net Calls
+$74​K
Net Calls Change
+$305​K

SWTX Hedge Fund Activity: Q3 2021 in Review

141 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2021, worth a combined $2.86B — down 23% from $3.69B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SWTX positions and 11 closed out — a net gain of 5 holders — while 59 added to existing stakes and 37 trimmed.

The largest buyer was Bank of America, adding an estimated $28.3M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $77.1M.

  • 141 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2021, up from 134 in Q2 2021.
  • Funds reported $2.86B of SpringWorks Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
  • 16 funds opened new SpringWorks Therapeutics positions in Q3 2021 and 11 closed out, a net change of +5 holders.
  • The largest SpringWorks Therapeutics buyer in Q3 2021 was Bank of America, an estimated $28.3M added.
  • The largest SpringWorks Therapeutics seller in Q3 2021 was Bain Capital Life Sciences Investors, an estimated $77.1M sold.

Based on aggregated 13F filings for Q3 2021.